PEPG Key Statistics, Chart & Performance
The current stock price of PEPG is 4.29 USD. In the past month the price decreased by -40%. In the past year, price increased by 245.97%.
PEPG Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to PEPG. When comparing the yearly performance of all stocks, PEPG is one of the better performing stocks in the market, outperforming 98.23% of all stocks.
PEPG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PEPG. No worries on liquidiy or solvency for PEPG as it has an excellent financial health rating, but there are worries on the profitability.
PEPG Financial Highlights
Over the last trailing twelve months PEPG reported a non-GAAP Earnings per Share(EPS) of -2.82. The EPS increased by 4.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.23% | ||
| ROE | -57.35% | ||
| Debt/Equity | 0 |
PEPG Forecast & Estimates
12 analysts have analysed PEPG and the average price target is 10.2 USD. This implies a price increase of 137.76% is expected in the next year compared to the current price of 4.29.
PEPG Ownership
PEPG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.08 | 383.716B | ||
| AMGN | AMGEN INC | 16.32 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.72 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.25 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.25 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PEPG
Company Profile
PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Company Info
PEPGEN INC
245 Main St, 2nd Floor
Cambridge MASSACHUSETTS US
Employees: 81
Phone: 17034568000
PEPGEN INC / PEPG FAQ
What does PEPGEN INC do?
PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
What is the stock price of PEPGEN INC today?
The current stock price of PEPG is 4.29 USD. The price decreased by -12.63% in the last trading session.
Does PEPG stock pay dividends?
PEPG does not pay a dividend.
What is the ChartMill rating of PEPGEN INC stock?
PEPG has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
When does PEPGEN INC (PEPG) report earnings?
PEPGEN INC (PEPG) will report earnings on 2026-02-23, after the market close.
Can you provide the ownership details for PEPG stock?
You can find the ownership structure of PEPGEN INC (PEPG) on the Ownership tab.